Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs. - Wikidata - awgldk - TriplyDB

Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.

Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.

http://www.wikidata.org/entity/Q33926200

about

Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy Relevance of tumor-infiltrating lymphocytes in breast cancer Antibody-based immunotherapy of solid cancers: progress and possibilities Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy Minireview: Regulatory T Cells and Ovarian Cancer.Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity.Immune checkpoint inhibitors in clinical trials Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging Enhanced CD8 T cell responses through GITR-mediated costimulation resolve chronic viral infection.Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure).Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models.miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint Immune based therapy for melanoma Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma.Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1.Mechanism of immune evasion in breast cancer.Stromal fibroblasts and the immune microenvironment: partners in mammary gland biology and pathology?Checkpoint inhibitors in immunotherapy of ovarian cancer.Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy.Programmed death-1 & its ligands: promising targets for cancer immunotherapy.Emerging immune checkpoints for cancer therapy.Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series.Clinical Applications of Immunotherapy Combination Methods and New Opportunities for the Future.The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application.Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities.Immune checkpoint inhibition in ovarian cancer.Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers.Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer.Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine.Fine needle aspirate flow cytometric phenotyping characterizes immunosuppressive nature of the mesothelioma microenvironment.Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8+ T cells Modulation of tumor immunity: a patent evaluation of WO2015026684A1.Murinization and H Chain Isotype Matching of the Anti-GITR Antibody DTA-1 Reduces Immunogenicity-Mediated Anaphylaxis in C57BL/6 Mice.Anti-GITR therapy promotes immunity against malignant glioma in a murine model.The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches.Next generation immune-checkpoints for cancer therapy.The Role of Immune Escape and Immune Cell Infiltration in Breast Cancer

P2860

Q26783783-D01FABF6-A026-4AF1-8C24-5AB4C65E3AAB Q26795598-9DE2224E-E112-4F9D-B7F2-BB7470DD8948 Q26796542-9D709BFB-F1F7-4EB7-A01C-8DAF4337DB06 Q28066199-FD0FC239-3EDF-4820-80B6-B9567EB6A71A Q30244214-C75E40F7-7E06-4BB3-AA15-FF1F625ECEEF Q33889105-D74D6885-C5FC-4F50-A8DB-4B6953B73B11 Q34309394-4A08E331-E98C-4270-A6FC-4DEB21CB7CC8 Q34502985-3D764CD7-18E2-4BAC-BF04-67C1363897D1 Q35147454-98113B2B-111B-47A4-94B1-B5A8D8FD10C0 Q35896426-DF794F08-3D7D-4E21-ADC8-FFCAEFBF5985 Q36024656-151E9925-611B-42CF-8555-56DE1666503B Q36360125-2EBAC266-B945-4B62-8F41-523A650B0128 Q36875531-979E34DB-09CA-46B4-8BC2-EA87E47D23C2 Q36876757-C60F3C56-5980-4D88-9FC3-08E10FEB1E01 Q36907372-EE78EE66-CA24-49AA-B083-145439E1231C Q37158481-DE2E83DA-DB70-4B8A-9C26-F79F22855632 Q37712385-95746F70-5679-49F2-97EC-C5AD4BB67FD7 Q38225334-A23EC45F-32AC-4C84-A75F-1D26823A38B9 Q38269568-4E0F629F-21EB-4766-8255-FD5B6FC7BB8D Q38548339-3C5D3E7D-541F-4235-83EC-130556D12198 Q38562062-4AB9AEAF-4B8B-492E-8F93-A7E4089E0AD1 Q38584979-3C8BB3C3-E6B9-4FB0-8E4A-A2A0FD95F61F Q38621228-6FEA59A2-8CE8-4121-AB81-AB8EF227019F Q38636430-846CE468-4B3A-42A4-A07B-6DD3D255CFA3 Q38666253-22B6BDB2-D232-48F8-9D35-9AEF74B433C2 Q38770458-F3A54DAB-7411-4A09-8CBA-EB4829BD7281 Q38770814-11C37EB4-7AAF-42C8-BEFC-24713AA59EE8 Q38800974-3FCDFB68-3E36-4FD3-992F-16498FB19C7E Q38806038-24D6551B-790E-439D-9877-12CDD62D3200 Q38838643-668B688E-BC63-45B8-A110-A2F6D793574B Q39402079-72650D91-5821-4ABD-82A6-70BC4C28066A Q40517920-6A570F54-2CDB-4D6E-B79E-1D81FBF3817B Q41557983-62206081-6D05-4297-A1DC-742950565EAD Q41701367-33119C58-5998-4ED8-98BF-18DE321EAD8B Q46640448-588FBBA0-BA32-4C3E-A950-48DAD646C128 Q48228066-B9141D9E-08CA-4C91-8CDA-E51887F96C83 Q48480477-92837167-037A-4000-9786-330DEB5F9B5B Q54980315-30854285-3A65-48F3-A788-761066881299 Q55383705-658DDD2D-40B8-4F78-A58C-A96F0DF39B45 Q57114285-E3757405-F096-41CF-A859-8502E052A9D5

P2860

Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.

http://www.wikidata.org/entity/Q33926200

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Combined PD-1 blockade and GIT ...... s with chemotherapeutic drugs.

@ast

Combined PD-1 blockade and GIT ...... s with chemotherapeutic drugs.

@en

type

label

Combined PD-1 blockade and GIT ...... s with chemotherapeutic drugs.

@ast

Combined PD-1 blockade and GIT ...... s with chemotherapeutic drugs.

@en

prefLabel

Combined PD-1 blockade and GIT ...... s with chemotherapeutic drugs.

@ast

Combined PD-1 blockade and GIT ...... s with chemotherapeutic drugs.

@en

P1433

Q33926200-C5FB836A-CA69-4819-9514-DF810A7BE316

P1476

Q33926200-B5453F96-773B-4839-87CC-F1DB1E3C4941

P2093

Q33926200-07C2E6AD-F2FA-4E9F-85B9-598B053D57C4

Q33926200-2B5B9CFA-D777-4803-9A33-DA12960099F5

Q33926200-3FE1FBBC-3313-419E-8047-908A06A58DB0

Q33926200-7A6D5A93-9AB2-496D-A879-252E2672B7AE

Q33926200-82CC412C-4182-4ECE-8421-9B41438FC3A5

Q33926200-C4409A89-118E-4793-B510-89A92616D3F2

P2860

Q33926200-08DB0782-4D2F-4FDB-B87F-5C6DBC708DC9

Q33926200-0E66FDA6-9F2E-4C14-A9C6-C65748C6E7A0

Q33926200-1041610F-8FE8-4778-A45D-664AD463067E

Q33926200-29D7F222-628E-4BC2-9C63-4C7AC4144AC4

Q33926200-35E79307-B8BF-4204-ADE5-276AB912A353

Q33926200-3A511AAB-3135-47B6-8621-9125C9E7CBB9

Q33926200-414DFBE4-2915-46D8-87D8-63ED3C56FD5B

Q33926200-44F35544-6492-45B5-9C25-0CC7020E5242

Q33926200-493054E7-1BD4-4373-B6FE-5318CD9B96C5

Q33926200-4B280F57-70F9-49A0-B680-E0226AB8AC09

P2888

Q33926200-F3AE21C4-F747-47CD-9973-1F2753E7499F

P304

Q33926200-8BE5A553-E8CC-481F-8B61-3CA5F42439A6

P31

Q33926200-7C331D80-0671-4C9E-9129-1F57605780C1

P356

Q33926200-7B409B33-ECEC-4CFF-849C-601317C55773

P478

Q33926200-5B38BC2F-21F9-4A6E-B116-97097E780DCF

P577

Q33926200-8CE47021-FC12-4C88-AE2A-4C9352270F51

P5875

Q33926200-2A4124E3-4C0B-4DFC-895F-6FE7C8F2085E

P6179

Q33926200-36FD0A60-2387-4F3B-96FE-71F0F6A91730

P698

Q33926200-2DF4CE1F-1693-4BDD-912E-A56FD5D34AFB

P921

Q33926200-C662E7DB-53B4-4EA5-A71A-A8EF0C87CD3E

P932

Q33926200-C6C75E55-6C87-41A9-B256-909C1C3B7357

P356

1479-5876-12-36

P1433

Journal of Translational Medicine

P1476

Combined PD-1 blockade and GIT ...... s with chemotherapeutic drugs.

@en

P2093

Bin Zhang

http://www.w3.org/2001/XMLSchema#string

Hongzan Ji

http://www.w3.org/2001/XMLSchema#string

Lei Lu

http://www.w3.org/2001/XMLSchema#string

Rongsheng Zhang

http://www.w3.org/2001/XMLSchema#string

Xiaobing Xu

http://www.w3.org/2001/XMLSchema#string

Xuan Wang

http://www.w3.org/2001/XMLSchema#string

P2860

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

Global cancer statistics

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer

Cancer treatment and survivorship statistics, 2012

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

TNF/TNFR family members in costimulation of T cell responses

Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production

P2888

1479-5876-12-36

P304

36

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1479-5876-12-36

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2014-02-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260119263

http://www.w3.org/2001/XMLSchema#string

P6179

1031646629

http://www.w3.org/2001/XMLSchema#string

P698

24502656

http://www.w3.org/2001/XMLSchema#string

P921

P932

4104995

http://www.w3.org/2001/XMLSchema#string